Resource Logo
PR Newswire

A Forward Look, the Year Ahead - Research Report on CBS Corporation, Comcast Corporation, Gilead Sciences Inc., Celgene Corporation and Kellogg Company


NEW YORK, February 20, 2013 /PRNewswire/ -- Today, National Traders Association announced new research reports highlighting CBS Corporation (NYSE:CBS), Comcast Corporation (NASDAQ:CMCSA), Gilead Sciences Inc. (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG) and Kellogg Company (NYSE:K). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

CBS Corporation Research Report

The great joy of earning better-than-expected revenues is evident for the Super Bowl ad time which CBS and its stakeholders are very much looking forward to. Analysts are expecting CBS to generate somewhere between $250 million to $300 million just for Super Bowl ad sales. Considering the large audience of the Super Bowl, someone always has to pay higher than usual. But, the big catch is the local ad sales which produce about 85% profit margin for the company. By all means, for a company that relies on ad sales, it may always be reasonable to pursue a case against someone deliberately taking away your profits from you - even if it means allocating a budget for litigation. The Full Research Report on CBS Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

Comcast Corporation Research Report

While it's high-time for Super Bowl and the growing business of advertisements, Comcast may also be earning better-than-expected revenues because of strong ad sales. Although ad sales are always worth the buzz, Comcast seems to be busy creating a series of waves that will mark another milestone for the company. Xfinity is Comcast's most recent premier project. Xfinity is a premier Internet destination that targets the African American community, in celebration of its culture, heritage and contributions to the global community. From US President Barack Obama to The Jackson 5, Comcast's Xfinity is worth the watch. The Full Research Report on Comcast Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

Gilead Sciences Inc. Research Report

Gilead has been getting the attention of analysts, investors, medical professionals and patients who have found hope in the world's largest maker of HIV drugs. During the last week of August 2012, the company launched the HIV drug Stribilid, or the "quad," which is a combination of four different medicines. Although the drug only had a few weeks of sales during Q3, the figures seem to be picking up. While sales of HIV drugs are continuing to increase, analysts and investors have other reasons to be bullish about the company. Gilead's acquisition of Pharmasset Inc., along with its highly coveted Sofusbivir hepatitis C drug, may help the company generate an additional $3.8 billion by 2020. The company is also investing on blood cancer drugs, and has reportedly spent $1.2 billion on blood cancer drugs. Gilead is still looking at great potentials to expand its offerings, and it is targeting to meet the significantly growing market demand for blood cancer treatments. The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

Celgene Corporation Research Report

Celgene's executives and stakeholders are delighted to celebrate a 14% increase in net product sales during Q4. Celgene's full year adjusted net income for 2012 reached $2.1 billion, a solid growth performance that accounts for the company's global market share. Celgene's net product sales for Abraxane and Vidaza saw a 3% increase, and a remarkable 17% increase for Revlimid. Celgene's Revlimid is probably one of its products which have been helping the company maintain its solid performance. Some analysts say that Celgene is still a good buy because of the catalysts that will drive the company to its $12 billion annual revenue by 2017. The most important factor that investors must focus on is each company's portfolio. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

Kellogg Company Research Report

Kellogg, best known for its ready-to-eat cereals, has since expanded to produce more food items like cookies, crackers, and potato chips, among others partly through its many acquisitions in the past. Its most recent purchase, Pringles, put the company in second place in the savory snack market behind Lays and Doritos maker PepsiCo. Motley Fool says both Kellogg and PepsiCo should benefit from rising income and increased urbanization outside the US, as demand for convenient pre-packaged food is likely to increase exponentially. In addition, Kellogg forged another deal for international growth with Singapore-based Wilmar International, which will manufacture, sell, and distribute Kellogg's brands in China. However, Zacks maintains its "neutral" rating on the company despite robust numbers, citing sluggish sales on its legacy cereals business and declines in its European business. Nevertheless, Kellogg's brand positioning, geographic diversity, cost-cutting, and the Pringles acquisition should counter these negatives. The Full Research Report on Kellogg Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Demi Lapierre
Main: +1-(702)-212-4493

National Traders Association


Copyright © 2013 -PR Newswire, Publisher. All rights reserved to PR Newswire.. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PR Newswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019.

Information in this article was accurate in February 20, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.